Spero Therapeutics - SPRO Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Spero Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares.
View analyst ratings for Spero Therapeutics or view top-rated stocks.

5 Wall Street analysts have issued twelve-month price objectives for Spero Therapeutics' stock. Their SPRO stock forecasts range from $5.00 to $70.00. On average, they expect Spero Therapeutics' stock price to reach $28.33 in the next year. This suggests a possible upside of 3,441.7% from the stock's current price.
View analysts' price targets for Spero Therapeutics or view top-rated stocks among Wall Street analysts.

Spero Therapeutics' stock was trading at $16.01 on January 1st, 2022. Since then, SPRO shares have decreased by 95.0% and is now trading at $0.80.
View the best growth stocks for 2022 here.

Spero Therapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 557,800 shares, an increase of 34.9% from the June 30th total of 413,600 shares. Based on an average trading volume of 713,200 shares, the short-interest ratio is presently 0.8 days. Currently, 2.3% of the company's shares are short sold.
View Spero Therapeutics' Short Interest.

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Spero Therapeutics.

Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings data on Monday, May, 16th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.87) by $0.14. The company earned $2.07 million during the quarter, compared to the consensus estimate of $2.85 million. Spero Therapeutics had a negative net margin of 792.03% and a negative trailing twelve-month return on equity of 116.93%. During the same quarter last year, the company posted ($0.66) EPS.

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Spero Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.40%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SPRO stock can currently be purchased for approximately $0.80.

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $26.26 million and generates $18.26 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

Spero Therapeutics employs 146 workers across the globe.

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for Spero Therapeutics is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.